Breaking News on Cosmetics Formulation & Packaging in North AmericaEU editionAPAC edition

Headlines > Business & Financial

Johnson & Johnson enters R&D collaboration with Intrexon

By Andrew McDougall+

06-Jan-2014

Johnson & Johnson has made moves to try and get ahead in the ever-competitive skin and hair care arenas by entering into a research and development collaboration with Intrexon Coproration.

As L’Oréal, Estee Lauder et al gear up to make 2014 their year in these fiercely competitive sectors, J&J Consumer & Personal Products Worldwide, a division of the U.S.-headquartered Consumer Company, has teamed up with the Germantown-based firm.

Intrexon Corporation is one of the leaders in synthetic biology and is focused on collaborating with companies in Health, Food, Energy and the Environment to create what is claimed to be biologically-based products that improve the quality of life and the health of the planet.

Through the company's proprietary UltraVector platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems.

The UltraVector platform delivers unprecedented control over the quality, function, and performance of living cells.

Advance skin and hair care

Johnson & Johnson will be utilizing the US company to help advance new skin and hair care products.

"We look forward to advancing new skin and hair beauty products that have measurable impact for consumers," says Randal J. Kirk, chairman and Chief Executive Officer at Intrexon.

"By combining Intrexon's synthetic biology approaches with the capabilities at Johnson & Johnson Innovation and Johnson & Johnson Consumer & Personal Products Worldwide, we believe that there are multiple areas for new product exploration."

Through the collaboration, technical experts at both companies will work together to explore, define, and test new potential products for consumers.

Another deal for Intrexon

It has been a busy start to the year for Intrexon, who has also agreed to acquire San Diego stem-cell company Medistem for about $26 million.

The deal is subject to regulatory and shareholder approval and Intrexon says the deal helps to complement the research and development collaboration with J&J.

Related products

Live Supplier Webinars

Explore how Snow Algae Powder stimulates longevity genes
Mibelle Biochemistry

On demand Supplier Webinars

Burns fat and achieves centimetric reduction
Provital Group
All supplier webinars